

Ondansetron (Zofran®)

Selected References:

- Andrade C. 2020. Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron. *J Clin Psychiatry*;81(3):20f13472
- Anderka M, et al. 2012. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol*; 94(1):22-30.
- Briggs GG, Freeman RK. 2014. *Drugs in Pregnancy and Lactation*. 10th edition. Philadelphia, PA: Wolters Kluwer (online version).
- Cao X, et al. 2022. Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis. *Front Pharmacol*, 13(951072).
- Cohen R, et al. 2014. Intestinal obstruction in pregnancy by ondansetron. *Reprod Toxicol*. 2014 Oct 24;50C:152-153.
- Cho Y, et al. 2025. Antiemetic use during pregnancy and child neurodevelopment: population-based birth cohort study. *BMC medicine*, 23(1), 667.
- Colvin L, et al. 2013. Off-label use of ondansetron in pregnancy in Western Australia. *Biomed Res Int*. 2013:909860.
- Danielsson B, Wikner BN, Kallen B. 2014. Use of ondansetron during pregnancy and congenital malformations in the infant. *Reprod Toxicol* 50:134-7.
- Diav-Citrin O, et al. 2017. Pregnancy outcome following in utero exposure to ondansetron: A prospective comparative, observational cohort study. *Reprod Toxicol*; 72:203.
- Dormuth CR, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. 2021. Comparison of Pregnancy Outcomes of Patients Treated with Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. *JAMA Netw Open*; 4(4):e215329.
- Einarson AK, et al. 2004. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG*;111:940-3.
- Elkomy MH, et al. 2015. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. *Clin Pharmacol Ther*. 97:167-76.
- Fejzo MS, et al. 2016. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. *Reprod Toxicol* 62: 87-91.
- Food and Drug Administration. 2012. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). <https://downloads.regulations.gov/FDA-2016-N-2462-0013/content.pdf>. Accessed 2018, 2022, and 2026.
- Huybrechts KF, et al. 2018. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. *JAMA*, 320(23), 2429-2437.
- Jelting Y, et al. 2017. Preventing nausea and vomiting in women undergoing regional anesthesia for cesarean section: Challenges and solutions. *Local Reg Anesth*, 10:83-90.
- Kaplan YC, et al. 2019. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systemic review and meta-analysis. *Reprod Toxicol*; 86 Jun:1-13.
- Larrimer MB, et al. 2014. Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. *Am J Obstet Gynecol* 210 (3): 270. e1-7
- Laspro M, et al. 2025. Association of Commonly Prescribed Antepartum Medications and Incidence of Orofacial Clefting. *The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association*, 62(7), 1164-1174
- Lavecchia M, et al. 2018. Ondansetron in Pregnancy and the Risk of Congenital Malformations: A Systematic Review. *J Obstet Gynaecol Can*. 40(7):910-918.
- Lemon LS, et al. 2020. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular

septal defect. *Int J Epidemiol*;49(2):648-656.

- Masarwe S, et al. 2023. Ondansetron use during pregnancy: Birth defects and obstetric outcomes. *Clin Nurs Res*, 32(4):705-711.
- Pasternak B. 2013. Ondansetron in pregnancy and risk of adverse fetal outcomes. *N Engl J Med* 368:814-823.
- Picot C, et al. 2020. Risk of malformation after ondansetron in pregnancy: An updated systemic review and meta-analysis. *Birth Defects Res*;112(13):996-1013.
- Reis ACC, et al. 2023. Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats. *Regul Toxicol Pharmacol*, 137:105302.
- Sakran R, et al. 2021. Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. *Reprod Toxicol*; 99:9-14.
- Schrager NL, et al. 2023. The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: Findings from the National Birth Defect Prevention Study. *Birth Defects Res*, 115(3):275-289.
- Sillis L, et al. 2026. Medications for Nausea and Vomiting of Pregnancy and the Risks for Adverse Birth Outcomes. *Pharmacoepidemiology and drug safety*, 35(4), e70367.
- Suarez EA, et al. 2021. Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. *Pharmacoepidemiol Drug Saf*; 30(2):114-125.
- Suarez EA, et al. 2021. Ondansetron use in early pregnancy and the risk of miscarriage. *Pharmacoepidemiol Drug Saf*; 30(2):103-113.
- Tolchinsky I, et al. 2026 Another prospective study on the safety of ondansetron for nausea and vomiting of pregnancy: addressing ongoing concerns. *Front. Pharmacol.* 17:1783632.
- Yang J, 2026. Ondansetron Use for Women With Hyperemesis Gravidarum and Risks of Spontaneous Abortion and Stillbirth: A Retrospective Cohort Study. *Pharmacoepidemiology and drug safety*, 35(2), e70335.
- Zhao W, et al. 2020. Retrospective comparison of the safety and effectiveness of dexmedetomidine versus standard of care before and during cesarean delivery in a maternity unit in Zhengzhou, China. *Med Sci Monit*, 26:e925709.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2026.

Ondansetron (Zofran®)

Selected References:

- Andersen JB, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. *European journal of neurology*; 30(1), 162-171.
- Bast N, et al. 2024. Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry. *Lancet Reg Health Eur*; 48: 101137.
- Ciplea AI, et al. 2020. Exposure to natalizumab during pregnancy and lactation is safe -Commentary. *Multiple sclerosis (Houndmills, Basingstoke, England)*; 26(8), 892-893.
- D'Amico E, et al. 2021. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. *Multiple sclerosis (Houndmills, Basingstoke, England)*; 27(14), 2284-2287.
- Demortiere S, et al. 2021. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. *Mult Scler*; 27(5):712-718.
- Ebrahimi N, et al. 2015. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. *Mult Scler*; 21(2):198-205.
- Friend S, et al. 2016. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. *BMC Neurol*; 16(1):150
- Gklinos P, et al. 2023. Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide. *Pharmaceuticals (Basel, Switzerland)*; 16(5),770.
- Godano E, et al. 2021. Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy. *Ital J Pediatr*; 47, 69.
- Guilloton L, et al. 2017. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. *J Gynecol Obstet Hum Reprod*; 46(3): 301-302.
- Haghighi A, et al. 2014. Natalizumab use during the third trimester of pregnancy. *JAMA Neurol*; 71(7): 891-895.
- Krysko KM, et al. 2023. Family planning considerations in people with multiple sclerosis. *Lancet Neurol*; 2023;22:350-66.
- Landi D, et al. 2022. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. *J Neurol Neurosurg Psychiatry jnnp-2022-329657*.
- Mahadevan U, et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. *Gastroenterology*; 156(5):1508-1524.
- Mahadevan U, et al. 2023. Global consensus statement on the management of pregnancy in inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2025;23(Suppl 11):S1-S60.
- Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. *Gastroenterology*; 155:696-704.
- Massarotti C, et al. 2021. Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. *Journal of clinical medicine*; 10(22), 5401
- O'Leary S, et al. 2023. Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis. *Journal of infusion nursing: the official publication of the Infusion Nurses Society*; 46(6), 347-359.
- Oreja-Guevara C, et al. 2023. Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements. *Cureus*; 15(8), e44056
- Peng A, et al. 2018. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. *J Neurol*

Sci; 396:202-205.

- Portaccio E, et al. 2018. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. *Neurology*; 90(10), e823-e831.
- Portaccio E, et al. 2022. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. *Mult Scler*; 28(13):2137-2141.
- Simone IL, et al. 2021. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies. *Frontiers in neurology*; 12, 697974.
- Ramesh V, et al. 2022. Adverse Obstetric Outcomes in Pregnant Women Using Natalizumab for the Treatment of Multiple Sclerosis: A Systematic Review. *Cureus*; 14(10), e29952
- Shipley J, et al. 2025. Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2. *Med J Aust*; 222:365-71.
- Siracusano M, et al. 2025. Maternal multiple sclerosis and offspring's developmental and behavioral profile: a case-control study. *Curr Neuropharmacol*; doi: 10.2174/011570159X370866250416103923. Epub ahead of print.
- Thiel S, et al. 2024. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. *J Neurol Neurosurg Psychiatry*; 95(6): 561-570.
- U.S. Food and Drug Administration. 2025. Tysabri (natalizumab) injection, for intravenous use: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125104s984lbl.pdf
- Yeh WZ, et al. 2021. MSBase Study Group. Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. *Neurology*; 96(24):e2989-3002.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2026.

Ondansetron (Zofran®)

Selected References:

- Biocon Biologics Inc. 2025. Semglee Product Label. National Institute of Health DailyMed database. Available

at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?>. Accessed May 2025.

- Bruttomesso D, et al. 2011. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). *Diabetes Metab*; 37(5):426-431.
- Callesen NF, et al. 2013. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. *J Matern Fetal Neonatal Med*; 26(6):588-592.
- Chico A, et al. 2016. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. *Eur J Obstet Gynecol Reprod Biol*; 206: 84-91.
- de Jong J, et al. 2016. Insulin analogues in pregnancy and specific congenital anomalies: a literature review. *Diabetes Metab Res Rev*; 32(4): 366-375.
- Di Cianni G, et al. 2005. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. *Diabetes Care*; 28:982-983.
- Di Cianni G, et al. 2008. Perinatal outcomes associated with the use of glargine during pregnancy. *Diabet Med*; 25(8):993-996.
- Dolci M, et al. 2005. Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison's Disease. *Diabetes Care*; 28:2084-2085.
- Eli Lilly and Company. 2025. Basaglar Product Label. National Institute of Health DailyMed database. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?>. Accessed May 2026.
- Gallen IW, et al. 2008. Survey of glargine use in 115 pregnant women with Type 1 diabetes. *Diabet Med*; 25(2):165-169.
- Holstein A, et al. 2003. Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. *Diabet Med*; 20:779-780.
- Imbergamo MP, et al. 2008. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. *Clin Ther*; 30(8):1476-1484.
- Lapolla A, et al. 2005. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? *Diabetes Metab Res Rev*; 21:241-52.
- Lepercq J, et al. 2010. Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes. *Diabetes Metab*; 36(3):209-212.
- Negrato CA, et al. 2010. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. *Diabetes Res Clin Pract*; 89(1):46-51.
- Pantalone KM, et al. 2011. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study-comment on Negrato et al. *Diabetes Res Clin Pract*; 93(1):e9-10.
- Pantalone KM, et al. 2011. Insulin glargine use during pregnancy. *Endocr Pract*; 17(3):448-55.
- Pollex E, et al. 2011. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. *Ann Pharmacother*; 45(1):9-16.
- Price N, et al. 2007. Use of insulin glargine during pregnancy: a case-control pilot study. *BJOG*; 114(4):453-457.
- Sanofi-Aventis U.S. 2023. Lantus Product Label. National Institute of Health DailyMed database. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?>. Accessed May 2026.
- Sonfi-Aventus U.S. 2025. Toujeo Product Label. National Institute of Health DailyMed database. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?>. Accessed May 2026.
- Torlone E, et al. 2007. Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. *Eur J Obstet Gynecol Reprod Biol*; 132(2):238-239.
- Westerbacka J, et al. 2025. Insulin glargine 300 U/mL safety data in pregnancy. *Diabetes Obes Metab*; 27(5):2322-2325.
- Woolderink JM, et al. 2005. Use of insulin glargine during pregnancy in seven type 1 diabetic women. *Diabetes Care*; 28:2594-2595.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2026.

Ondansetron (Zofran®)

Selected References:

- Albzeza W, et al. 2023. Efficacy and safety of preoperative melatonin for women undergoing cesarean section: a systematic review and meta-analysis of randomized placebo-controlled trials. *Medicina (Kaunas)*, 59(6):1065.
- Alkhfaji H, et al. 2023. Impact of melatonin as a premedication agent in caesarean section on blood loss and postoperative pain level. *Anesthesiol Res Pract*, 2023:8102111.
- Amaral FGD and José C. 2018. A brief review about melatonin, a pineal hormone. *Archives of Endocrinology and Metabolism*, 62(4):472-479
- American Academy of Neurology. 2019. Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder. Accessed May 11. 2026 from <https://pmc.ncbi.nlm.nih.gov/articles/PMC7238942/>
- Andersen LP, et al. 2016. The safety of melatonin in humans. *Clin Drug Investig*; 36:169-175.
- Davis, F. C. (1997). Melatonin: role in development. *Journal of Biological Rhythms*; 12(6):498-508.
- Díaz E, et al. 2000. Effect of prenatal melatonin on the gonadotropin and prolactin response to the feedback effect of testosterone in male offspring. *The Journal of Steroid Biochemistry and Molecular Biology*; 72(1):61-69.
- Díaz, E, et al. 1999. Prenatal melatonin exposure influences the maturation of gonadotropin and prolactin estradiol-benzoate feedback system. *The Journal of Steroid Biochemistry and Molecular Biology*; 70(1): 81-88.
- Ejaz F, et al. 2020. Maternal serum melatonin increases during pregnancy and falls immediately after delivery implicating the placenta as a major source of melatonin. *Frontiers in Endocrinology (Lausanne)*; 11:623038-623038.
- Garofoli F, et al. 2023. Fate of melatonin orally administered in preterm newborns: antioxidant performance and basis for neuroprotection. *J Pineal Res*; 76(1):e12932.
- Garofoli F, et al. 2021. Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial. *Trials*; 22(1):82.
- Gitto E, et al. 2011. Update on the use of melatonin in pediatrics. *J Pineal Res*; 50:21-8.
- Gowda SK. 2022. A comparative study to evaluate the effect of melatonin on blood loss after elective Caesarean section: a randomized double blind study. *Indian J Anaesth*; 66(Suppl 1):S17-S18.

- Grivas T, et al. 2007. Melatonin the “light of the night” in human biology and adolescent idiopathic scoliosis. *Scoliosis*; 2,6.
- Hardeland R. 2009. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatonergic agonists. *Neuropsychiatric Disease and Treatment*, 5:341–354.
- Harpsøe NG, et al. 2015. Clinical pharmacokinetics of melatonin: a systematic review. *Eur J Clin Pharmacol*, 71:901–909.
- Iavarone S, et al. 2023. Antiplatelet effect of melatonin through breastfeeding: a pediatric case report. *Children (Basel)*, 10(12):1839.
- Jayashree, et al. 2021. Effect of melatonin in reducing blood loss during and after caesarean section. *Int J Clin Obstet Gynecol*, 5(6):227–231.
- Katzer D, et al. 2016. Melatonin concentrations and antioxidative capacity of human breast milk according to gestational age and the time of day. *J Hum Lact*; 32:NP105–NP110.
- Khezri MB, et al. 2019. Effect of melatonin on blood loss after cesarean section: a prospective randomized double-blind trial. *J Obstet Gynaecol India*; 69(5):436–443.
- Luboshitzky R, et al. 2002. Melatonin administration alters semen quality in healthy men. *J Androl*; 4:572–578. Mannino G, et al. 2021. Melatonin and phytemelatonin: chemistry, biosynthesis, metabolism, distribution and bioactivity in plants and animals—an overview. *International Journal of Molecular Sciences*; 22(18):9996.
- Mejlhede MAB, et al. 2021. Oral melatonin supplementation during *in vitro* fertilization treatment: a systematic PRISMA review and meta-analysis of randomized controlled trials. *Gynecological Endocrinology*; 37(12):1079–1085.
- Moradi M, et al. 2021. Melatonin protects rats testes against bleomycin, etoposide, and cisplatin-induced toxicity via mitigating nitro-oxidative stress and apoptosis. *Biomed Pharmacother*; 138:111481.
- National Center for Complementary and Integrative Health. 2023. Attention deficit hyperactivity disorder (ADHD) and complementary health approaches: What the science says. Accessed on May 11, 2026 from <https://www.nccih.nih.gov/health/providers/digest/adhd-and-complementary-health-approaches-science>
- Okatani Y, et al. 2001. Effect of prenatal melatonin exposure on gonadotropins and prolactin secretion in male and female rat pups. *European Journal of Pharmacology*; 424(3):229–235.
- Ramiro-Cortijo D, et al. 2020. Maternal antioxidant status in early pregnancy and development of fetal complications in twin pregnancies: a pilot study. *Antioxidants*; 9(4):269
- Reiter RJ, et al. 2024. Melatonin-mediated actions and circadian functions that improve implantation, fetal health and pregnancy outcome. *Reproductive toxicology (Elmsford, N.Y.)*, 124, 108534.
- Showell MG, et al. 2020. Antioxidants for female subfertility. *Cochrane Database Syst Rev*, 8(8):CD007807.
- Sun TC, et al. 2020. Protective effects of melatonin on male fertility preservation and reproductive system. *Cryobiology*, 95:1–8
- Vine T, et al. 2022. Melatonin use during pregnancy and lactation: a scoping review of human studies. *Braz J Psychiatry*, 44(3):342–348.
- Voordouw BCG, et al. 1992. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. *J Clin Endocrinol Metab*; 74:108–117.
- Yang HL, et al. 2018. Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. *Am J Reprod Immunol*, 80(1):e12839.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2026.

Ondansetron (Zofran®)

Selected References:

- Anghelescu I, et al. 2004. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. *J Clin Psychiatry*; 65:1286-1287.
- Biesdorf C, et al. 2019. Physiologically-based pharmacokinetics of ziprasidone in pregnant women. *Br J Clin Pharmacol*; 85(5):914-923.
- Bode'n R, et al. 2012. Antipsychotics During Pregnancy Relation to Fetal and Maternal Metabolic Effects. *Arch Gen Psychiatry*; 69(7):715-721.
- Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. *J Affect Disord*; 373:495-504.
- Creeley CE, et al. 2019. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. *Brain Sci*; 9(9),235.
- Damkier P, Videbech P. 2018. The safety of second-generation antipsychotics during pregnancy: A clinically focused review. *CNS Drugs*. 32(4):351-366.
- Einarson A, Boskovic R. 2009. Use and safety of antipsychotic drugs during pregnancy. *J Psychiatr Pract*; 15(3):183-192.
- FDA. 2011. Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns (issued 2/2011). <https://www.fda.gov/Drugs/DrugSafety/ucm243903.htm>
- FDA 2014. Drug Safety Communication: FDA reporting mental health drug ziprasidone (Geodon) associated with rare but potentially fatal skin reactions. (Issued 12/2014). <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-reporting-mental-health-drug-ziprasidone-geodon-associated-rare>.
- Ginsberg DL. 2003. Ziprasidone-induced galactorrhea. *Prim Psychiatry*; 10:22-23.
- Ginsberg DL. 2004. Ziprasidone-induced hyperprolactinemia. *Prim Psychiatry*; 11:26-27.
- Goodnick PJ, et al. 2002. Antipsychotics: Impact on prolactin levels. *Expert Opin Pharmacother*; 3:1381-1391.
- Haddad PM, Wieck A. 2004. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. *Drugs*; 64:2291-2314.
- Heinonen E, et al. 2022. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. *CNS drugs*; 36(5):529-539.
- Humby T, Davies W. 2019. Brain gene expression in a novel mouse model of postpartum mood disorder. *Trans Neurosci*; 10:168-174.
- Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatr*; 73(9):938-46.
- Huybrechts KF, et al. 2023. Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US. *JAMA psychiatry*; 80(2):156-166.

- Jordan MP. 2003. Ziprasidone-associated galactorrhea in a female teenager. *J Am Acad Child Adolesc Psychiatry*; 42:4-5.
- Khan SJ, et al. 2016. Bipolar disorder in pregnancy and postpartum: Principles of management. *Curr Psychiatry Rep*; 18(2):13.
- Kopecek M, et al. 2005. Ziprasidone-induced galactorrhea: A case report. *Neuro Endocrinol Lett*; 26:69-70.
- Kulkarni J, et al. 2015. Antipsychotic use in pregnancy. *Expert Opin Pharmacother*; 16(9):1335-1345.
- Lusskin SI, et al. 2004. Prolactin Elevation with Ziprasidone. *American Journal of Psychiatry*; 161(10): 1925.
- Maguire GA. 2002. Prolactin elevation with antipsychotic Medications: Mechanisms of action and clinical consequences. *J Clin Psychiatry*; 63 Suppl 4:56-62.
- McCauley-Elsom K, et al. 2010. Antipsychotics in pregnancy. *Psychiat Ment Health Nurs* 17(2):97-104.
- Myers WT. 2014. A lactating adolescent on atypical antipsychotics: A case report of an emerging challenge. *J Investig Med*; 62:485.
- Park Y, et al. 2018. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. *Am J Psychiatry*; 175(6):564-574
- Peitl MV, et al. 2010. Ziprasidone as a possible cause of cleft palate in a newborn. *Psychiatr Danub*; 22(1):117-119.
- Ramadan M, et al. 2005. D2-blockade and possible ziprasidone-induced galactorrhea. *Int Clin Psychopharmacol*; 20:113-114.
- Raza S, Haq F. 2010. Ziprasidone-induced galactorrhea in an adolescent female: A case report. *Prim Care Companion J Clin Psych*; 12(3):PCC.09I00855
- Ruzic K, et al. 2009. Pregnancy and atypical antipsychotics. *Psychiatr Danub*; 21(3):368-370.
- Saldaña SN, Delgado SV. 2007. Ziprasidone-associated galactorrhea in an adolescent female. *J Child Adolesc Psychopharmacol*; 17:259-260.
- Schlotterbeck P, et al. 2009. Low concentration of ziprasidone in human milk: a case report. *Int J Neuropsychopharmacology*; 12(3) 437-438.
- Sørensen MJ, et al. 2015. Risk of fetal death after treatment with antipsychotic medications during pregnancy. *PLoS One*; 10(7): e0132280.
- Straub L, et al. 2026. Congenital malformation risk following prenatal antipsychotic exposure: a systematic safety surveillance approach. *BMJ Ment Health*; 29(1):e302270.
- Wang E, et al. 2025. Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes. *CNS Drugs*; 391-22.
- Werremeyer A. 2009. Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. *Am J Psychiatry*; 166(11):1298.
- Uguz F. 2016. Second-generation antipsychotics during the lactation period: A comparative systematic review on infant safety. *J Clin Psychopharmacol*; 36:244-252.
- Uguz FJ. 2019. Antipsychotic use during pregnancy and the risk of gestational diabetes mellitus: A systematic review. *Clin Psychopharmacol*; 39(2):162-167.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2026.